Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) have earned an average recommendation of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued a report on the stock in the last year is $24.57.
AVDL has been the topic of several recent research reports. Rodman & Renshaw assumed coverage on Avadel Pharmaceuticals in a report on Wednesday, June 12th. They set a “buy” rating and a $27.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Avadel Pharmaceuticals in a report on Wednesday, August 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Wednesday, September 4th.
View Our Latest Analysis on AVDL
Institutional Trading of Avadel Pharmaceuticals
Avadel Pharmaceuticals Stock Performance
Shares of NASDAQ AVDL opened at $13.40 on Wednesday. Avadel Pharmaceuticals has a fifty-two week low of $9.50 and a fifty-two week high of $19.09. The company has a market cap of $1.29 billion, a PE ratio of -7.20 and a beta of 1.53. The business has a 50-day simple moving average of $15.51 and a two-hundred day simple moving average of $15.94.
Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The firm had revenue of $41.50 million for the quarter, compared to analyst estimates of $37.47 million. Avadel Pharmaceuticals had a negative return on equity of 122.64% and a negative net margin of 111.64%. The business’s revenue was up 2666.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. On average, sell-side analysts predict that Avadel Pharmaceuticals will post -0.5 earnings per share for the current fiscal year.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Featured Stories
- Five stocks we like better than Avadel Pharmaceuticals
- 3 Stocks to Consider Buying in October
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- 3 Warren Buffett Stocks to Buy Now
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Top Biotech Stocks: Exploring Innovation Opportunities
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.